SteelPeak Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

SteelPeak Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Hold	0	–	-$65.2K	–	583
2025 Q2	–	Hold	0	–	–	–	540

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SteelPeak Wealth's ALNY Position: Q1 2026 in Review

SteelPeak Wealth sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 1,484 shares — an estimated $590K sold.

SteelPeak Wealth first reported a position in ALNY in Q2 2022 and held it in 15 quarters. The position peaked at $1.03M in Q1 2024. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

SteelPeak Wealth reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
SteelPeak Wealth sold 1,484 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $590K.
SteelPeak Wealth first reported a position in Alnylam Pharmaceuticals in Q2 2022 and held it in 15 quarters.
SteelPeak Wealth's Alnylam Pharmaceuticals position peaked at $1.03M in Q1 2024.
787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on SteelPeak Wealth's 13F filing for Q1 2026, filed 5 May 2026.